Lupin receives tentative approval for Generic Avelox Tablets
From USFDA
Lupin announced that its US subsidiary, Gavis Pharmaceuticals LLC, USA has received tentative approval for its Moxifloxacin Hydrochloride Tablets, 400 mg from the United States Food and Drug Administration to market generic of Bayer Healthcare Pharmaceuticals Inc's Avelox Tablets, 400 mg (base).Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content